Study of Daily Pentoxifylline as a Rescue Treatment in Duchenne Muscular Dystrophy
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to see if male children with Duchenne muscular dystrophy (DMD) have changes in strength when given the drug Pentoxifylline as a rescue treatment. A total of 64 subjects are expected to participate through all other centers of the Cooperative International Neuromuscular Research Group (CINRG) worldwide.
The primary purpose of this study is to see whether the addition of pentoxifylline to a steroid regimen is effective in treating deteriorating muscle strength by comparing the muscle strength of PTX treated subjects and placebo treated subjects.
| Condition | Intervention | Phase |
|---|---|---|
|
Muscular Dystrophy, Duchenne |
Drug: Pentoxifylline |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Treatment |
| Official Title: | A Double-Blinded Randomized Placebo Controlled Study of Daily Pentoxifylline as a Rescue Treatment in DMD |
- Quantitative muscle strength will be measured using a CINRG Quantitative Muscle System (CQMS). The highest value of two consecutive maximal efforts will be recorded. The primary strength endpoint will be total CQMS score. [ Time Frame: January 2008 ] [ Designated as safety issue: No ]
- Strength of arm, leg and grip QMT scores Measured Screening and Months 1, 3, 6, 9 & 12 [ Time Frame: January 2008 ] [ Designated as safety issue: No ]
- Manual Muscle Testing (MMT) score measured at screening and months 1, 3, 6, 9 & 12 using the Medical Research Council (MRC) scoring system. [ Time Frame: January 2008 ] [ Designated as safety issue: No ]
- Functional evaluations measured at screening and months 1, 3, 6, 9 & 12 [ Time Frame: January 2008 ] [ Designated as safety issue: No ]
- Time function assessments, including time rising from the floor, time to climb four standard stairs, and time to walk 10 meters. They will be measured at screening and months 1, 3, 6, 9 & 12. [ Time Frame: January 2008 ] [ Designated as safety issue: No ]
- pulmonary function test (PFA's) measured at screening and months 1, 3, 6, 9 & 12 [ Time Frame: January 2008 ] [ Designated as safety issue: No ]
- Pediatric Quality of Life (PQOL) measured at screening and months 1, 3, 6, 9 & 12 [ Time Frame: January 2008 ] [ Designated as safety issue: No ]
- Goniometry measured at screening and months 1, 3, 6, 9 & 12 [ Time Frame: January 2008 ] [ Designated as safety issue: No ]
- TNF-alpha and TGF-beta measured at screening and months 1, 3, 6, 9 & 12 [ Time Frame: February 2008 ] [ Designated as safety issue: No ]
| Enrollment: | 64 |
| Study Start Date: | September 2005 |
| Study Completion Date: | January 2008 |
| Primary Completion Date: | December 2007 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1
Pentoxifylline
|
Drug: Pentoxifylline
Participants will be randomized to receive either pentoxifylline or placebo in addition to their stable steroid therapy. Active drug and placebo preparations will be supplied as gel capsules of identical size, appearance and taste. Active drug capsules will contain one 400 mg time-release pentoxifylline tablet and inert filler. Placebo capsules will contain inert filler. Based on weight at screening, <30 mg will receive 1 400 capsule/day; 30-49 kg will receive two 400 capsules/day; 50 kg or greater will receive three 400 mg capsules/day. Other Name: Trental
|
|
No Intervention: 2
Placebo
|
Detailed Description:
DMD is the most common and devastating type of muscular dystrophy (incidence 1 in 3500 live born males worldwide). DMD is characterized by a complete loss of dystrophin, leading to progressive muscle weakness and wasting.
No cure is currently available despite our present understanding of the disorder and the discovery and characterization of the causative gene and its protein product dystrophin in 1987. Corticosteroids (prednisone, deflazacort) may delay disease progression and until now it is the only treatment that proved to be beneficial for patients with DMD. Other alternative supplements like creatine and glutamine also delay diseased progression.
Eligibility| Ages Eligible for Study: | 7 Years and older |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male
- Age 7 years to 100 years
- Ability to ambulate for 10 meters. Assistive devices are allowed.
- Diagnosis of DMD confirmed by at least one the following:
- On stable dose of prednisone, prednisolone or deflazacort for at least 12 months prior to screening.
- Participants who are on stable dose of any combination of the following compounds (creatine, glutamine, coenzyme Q10, vitamin E, C or D, JUVEN, arginine, calcium) must have taken these medications for at least 2 months prior to screening. Subjects are not required to take these medications to participate in the study.
- All other herbs, supplements or green tea (other than those noted above) have been discontinued 3 months prior to screening.
- Ability to provide reproducible QMT bicep score with no more than 15% variation between scores during screening.
- Normal blood clotting ability evidenced by a platelet function assessment (PFA).
Exclusion Criteria:
- Currently enrolled in another treatment clinical trial.
- History of significant concomitant illness or significant impairment of renal or hepatic function.
- History of impairment of blood clotting ability (as evidenced by increased PT/PTT or PFA over the upper limit of normal (ULN)).
- Recent cerebral or retinal hemorrhage.
- History of bleeding diathesis or gastric ulcer.
Contacts and Locations| United States, District of Columbia | |
| Children's National Medical Center | |
| Washington, District of Columbia, United States, 20010 | |
| United States, Minnesota | |
| Mayo Clinic | |
| Rochester, Minnesota, United States, 55905 | |
| United States, Missouri | |
| Washington University, St. Louis | |
| St. Louis, Missouri, United States, 63110 | |
| United States, Pennsylvania | |
| Children's Hospital of Pittsburgh | |
| Pittsburgh, Pennsylvania, United States, 15213 | |
| United States, Tennessee | |
| University of Tennessee | |
| Memphis, Tennessee, United States, 38104 | |
| Argentina | |
| Hospital Frances | |
| Buenos Aires, Argentina, 1434 | |
| Australia, Victoria | |
| Children's Hospital | |
| Melbourne, Victoria, Australia, 3052 | |
| Canada, Alberta | |
| Alberta Children's Hospital | |
| Calgary, Alberta, Canada, T2T 5C7 | |
| University of Alberta | |
| Edmonton, Alberta, Canada, T6G 2J3 | |
| Israel | |
| Hadassah Hospital, Mt. Scopus | |
| Jerusalem, Israel, 91240 | |
| Italy | |
| IRCCS C Mondino Foundation | |
| Pavia, Italy, 27100 | |
| Study Chair: | Diana Escolar, MD | Children's National Medical Center, Center for Genetic Medicine |
More Information
Additional Information:
No publications provided
| Responsible Party: | Study Chair, CINRG |
| ClinicalTrials.gov Identifier: | NCT00243789 History of Changes |
| Other Study ID Numbers: | CNMC0705 |
| Study First Received: | October 21, 2005 |
| Last Updated: | October 26, 2011 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Cooperative International Neuromuscular Research Group:
|
Duchenne Genetic Muscular Dystrophy DMD |
Additional relevant MeSH terms:
|
Muscular Dystrophy, Duchenne Muscular Dystrophies Muscular Disorders, Atrophic Muscular Diseases Musculoskeletal Diseases Neuromuscular Diseases Nervous System Diseases Genetic Diseases, X-Linked Genetic Diseases, Inborn Pentoxifylline Phosphodiesterase Inhibitors Enzyme Inhibitors |
Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Platelet Aggregation Inhibitors Hematologic Agents Therapeutic Uses Radiation-Protective Agents Protective Agents Physiological Effects of Drugs Vasodilator Agents Cardiovascular Agents Free Radical Scavengers Antioxidants |
ClinicalTrials.gov processed this record on May 19, 2013